6238-30-8

Basic information

• Product Name: 3-HYDROXYQUINUCLIDINE-3-CARBONITRILE
• Synonyms: BUTTPARK 95\04-18;3-HYDROXYQUINUCLIDINE-3-CARBONITRILE;3-Quinuclidinol cyanohydrine;3-Cyano-3-quinuclidinol;3-CYANO-3-HYDROXYQUINUCLIDINE;3-QUINUCLIDINOL CYANOHYDRIN;RaceMic 3-cyano-3-quinuclidinol
• CAS NO: 6238-30-8
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19
• Mol File: 6238-30-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 156 °C
• Boiling Point: 534.7°C at 760 mmHg
• Flash Point: 277.2°C
• Appearance: /
• Density: 1.54g/cm³
• Vapor Pressure: 2.89E-12mmHg at 25°C
• Refractive Index: 1.752
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-HYDROXYQUINUCLIDINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYQUINUCLIDINE-3-CARBONITRILE(6238-30-8)
• EPA Substance Registry System: 3-HYDROXYQUINUCLIDINE-3-CARBONITRILE(6238-30-8)

Safety Data

• Hazard Codes: Xn:Harmful
• Statements: R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
• Safety Statements: S36/37:Wear suitable protective clothing and gloves.
• HazardClass: IRRITANT
• Hazardous Substances Data: 6238-30-8(Hazardous Substances Data)

Usage

General Description

3-Hydroxyquinuclidine-3-carbonitrile is a chemical compound that is used in the pharmaceutical industry for the synthesis of various organic compounds. It is a derivative of quinuclidine, which is a bicyclic amine with a five-membered nitrogen-containing ring. 3-Hydroxyquinuclidine-3-carbonitrile is used as a building block in the production of pharmaceutical drugs, particularly those aimed at treating central nervous system disorders. Its unique structure and chemical properties make it a valuable intermediate for the synthesis of a wide range of biologically active molecules, demonstrating its importance in drug discovery and development.

InChI:InChI=1/C19H16N4O4S2/c24-8-6-20-16-13(17(25)22-7-2-1-5-15(22)21-16)10-14-18(26)23(19(28)29-14)11-12-4-3-9-27-12/h1-5,7,9-10,20,24H,6,8,11H2

Upstream product

• 151-50-8 potassium cyanide 
• 1193-65-3 3-quinuclidinone hydrochloride 
• 143-33-9 sodium cyanide 
• 3731-38-2 3-Quinuclidinone 
• 39896-06-5 quinuclidine hydrochloride 

Downstream Products

• 26630-16-0 3-morpholino-3-cyanoquinuclidine 
• 81547-25-3 quinuclidine-3-spiro-5'-oxazolidine-2',4'-dione 
• 6238-31-9 (+/-)-ethyl 3-hydroxy-1-azabicyclo[2.2.2]octane-3-carboxylate 
• 128223-36-9 2'-(1H-indol-3-yl)spiro(1-azabicyclo<2.2.2>octane-3,5'(4'H)-oxazole) dihydrochloride 
• 128199-67-7 2'-(1-methyl-1H-indol-3-yl)spiro(1-azabicyclo<2.2.2>octane-3,5'(4'H)-oxazole) dihydrochloride 
• 138982-76-0 C₁₆H₂₀N₂O₂*2ClH 
• 128199-81-5 C₁₇H₁₈N₂OS*2ClH 
• 128199-86-0 C₁₆H₁₈N₄O*3ClH 
• 128199-90-6 C₁₉H₂₃N₃O*2ClH 
• 128199-91-7 C₁₉H₂₃N₃O*2ClH 
• 128199-70-2 [2'-(5-fluoro-1-methyl-1H-indol-3-yl)]spiro(1-azabicyclo[2.2.2]octane-3,5'(4'H)-oxazole) 
• 128199-88-2 C₁₉H₂₃N₃O₂*2ClH 
• 128199-84-8 2'-(5-amino-1-methyl-1H-indol-3-yl)spiro(1-azabicyclo<2.2.2>octane-3,5'(4'H)-oxazole) trihydrochloride 
• 128199-87-1 C₁₈H₂₀N₄O₃*2ClH 

Relevant articles and documents

NOVEL SPIRO-QUINUCLIDINYL DERIVATIVES FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM DISORDERS

-

Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders

The present invention is directed to novel spiro-quinuclidinyl derivatives, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

Novel 5-HT3 antagonists: Indol-3-ylspiro(azabicycloalkane-3,5'(4'H)- oxazoles)

The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.